Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

NCT00371345 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Metastasis

Interventions

DRUG: Dasatinib
DRUG: Dasatinib 100 mg

Sponsor

Bristol-Myers Squibb